A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

NCT05007652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma and Malignant Lymphoma

Interventions

DRUG: KRN125(pegfilgrastim), PLR001(plerixafor)
DRUG: KRN8601(filgrastim), PLR001(plerixafor)

Sponsor

Kyowa Kirin Co., Ltd.